BioMarin Pharma (BMRN) Misses Q1 EPS by 14c
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $54.69 --0%
Revenue Growth %: +13.2%
Financial Fact:
Equity in the loss of BioMarin/Genzyme LLC: -104K
Today's EPS Names:
OCCI, MAYS, CRMT, More
Revenue Growth %: +13.2%
Financial Fact:
Equity in the loss of BioMarin/Genzyme LLC: -104K
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q1 EPS of ($0.32), $0.14 worse than the analyst estimate of ($0.18). Revenue for the quarter came in at $400 million versus the consensus estimate of $389.69 million.
- 2019 Full-Year Financial Guidance unchanged
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ennis (EBF) Reports In-Line Q1 EPS
- Seacoast Banking (SBCF) PT Raised to $34 at Piper Sandler
- Morgan Stanley Downgrades Sands China Ltd. (1928:HK) (SCHYY) to Equalweight
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
